A Soviet-era stimulant relative of the first memory drug, taken in month-long courses. The strongest human signal is reduced persistent fatigue, though almost all evidence is Russian, industry-linked and unrepeated elsewhere. Side effects look mild and reversible, mainly sleeplessness and irritability. Supply outside Russia is unregulated and often misdeclared; tested athletes face a ban. Long-term use is unstudied. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Seated blood pressure | 105/65 to 120/75 mmHg | Detects a stimulant-driven blood-pressure rise |
| Resting heart rate | 50–65 beats per minute | Detects fight-or-flight load from the drug |
| Total sleep time and time taken to fall asleep | 7–9 hours; onset under 20 minutes | Insomnia is the most frequent adverse effect |
| MFI-20 fatigue score | No established target; track the change from the individual's own baseline | Quantifies the primary claimed benefit instead of relying on impression |
| ALT | 10–20 U/L | Screens liver tolerability before and between courses |
| eGFR | Above 90 mL/min/1.73 m² | The drug leaves the body largely unchanged via the kidneys, so clearance sets exposure |
| Fasting glucose | 75–86 mg/dL | Animal work showed glucose and fat-mass effects that have never been tested in people |
| HbA1c | Below 5.4% | Confirms whether any fasting-glucose shift is real or incidental |
| TSH | 0.5–2.0 mIU/L | Excludes an underactive thyroid as the competing cause of the fatigue |
| Ferritin | 50–150 ng/mL (menstruating women 50–100 ng/mL) | Excludes iron deficiency, which causes fatigue long before anaemia appears |
| Vitamin B12 | 500–900 pg/mL | Excludes a B12 deficit producing fatigue and cognitive complaints |
Cadence: Blood pressure and heart rate twice weekly through the first month; fatigue re-scored at day 30 against baseline; the laboratory panel repeated only where courses recur, at roughly every six months; sleep tracked continuously with a wearable throughout each course.